- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
- Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
- Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
- Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
- Alvotech S.A. Annual General Meeting to be held June 7, 2024
- Aðalfundur Alvotech S.A. boðaður 7. júní 2024
- Alvotech kynnir uppgjör fyrsta ársfjórðungs 2024 22. maí nk. kl. 12 að íslenskum tíma
- Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
More ▼
Key statistics
On Thursday, Alvotech SA (ALVO:ICX) closed at 1,875.00, -25.00% below its 52-week high of 2,500.00, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1,945.00 |
---|---|
High | 1,945.00 |
Low | 1,850.00 |
Bid | 1,860.00 |
Offer | 1,875.00 |
Previous close | 1,945.00 |
Average volume | 176.60k |
---|---|
Shares outstanding | 302.73m |
Free float | 72.59m |
P/E (TTM) | -- |
Market cap | 4.24bn USD |
EPS (TTM) | -2.05 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:40 BST.
More ▼